This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Pathogenesis

Authoring team

Multiple sclerosis is an autoimmune disease.

The cause is unknown, but it appears to involve a combination of genetic susceptibility and a nongenetic trigger, such as a virus, metabolism, or environmental factors, that together result in a self-sustaining autoimmune disorder that leads to recurrent immune attacks on the CNS.

It is proposed that an unknown non-self antigen mimics proteins in myelin. This antigen is presented on the surface of macrophages in combination with class 2 MHC.

The resulting stimulation of Th1 T helper lymphocytes causes their expression of LFA-1 and VLA-4. These T helper cells may now bind to the cognate adhesion molecules, ICAM-1 and VCAM-1, on vascular endothelial cells. The release of proteases permits the T helper cells to cross the endothelium and enter the central nervous system.

The destruction of myelin proceeds in three ways:

  • TNF-alpha from Th1 lymphocytes
  • TNF-alpha, oxygen free radicals, nitric oxide and proteases from activated macrophages
  • antibody mediated complement activation

Multiple sclerosis has classically been considered to be primarily a demyelinating disease. It is clear that neuronal death occurs from the early stages of the disease. It is probably this process of neuronal loss which contributes to the accumulating disability in multiple sclerosis.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.